Draft:MoonLake Immunotherapeutics: Difference between revisions
Task 3: Disable the categories on this page while it is still a draft, per WP:DRAFTNOCAT/WP:USERNOCAT |
Submitting using AfC-submit-wizard |
||
| Line 1: | Line 1: | ||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
{{AfC submission|||ts=20241114091843|u=130.225.188.129|ns=118}} |
|||
{{AFC submission|d|corp|u=Pomelosol|ns=118|decliner=CFA|declinets=20240727210303|ts=20240403151046}} <!-- Do not remove this line! --> |
{{AFC submission|d|corp|u=Pomelosol|ns=118|decliner=CFA|declinets=20240727210303|ts=20240403151046}} <!-- Do not remove this line! --> |
||
{{AFC submission|d|corp|u=Pomelosol|ns=118|decliner=Theroadislong|declinets=20240327103927|small=yes|ts=20240327100205}} <!-- Do not remove this line! --> |
{{AFC submission|d|corp|u=Pomelosol|ns=118|decliner=Theroadislong|declinets=20240327103927|small=yes|ts=20240327100205}} <!-- Do not remove this line! --> |
||
| Line 9: | Line 13: | ||
---- |
---- |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
MoonLake Immunotherapeutics (‘MoonLake’) ([[Nasdaq|NASDAQ]]: MLTX) is a clinical-stage biopharmaceutical company, headquartered in [[Zug]], [[Switzerland]], focused on developing medicines for inflammatory diseases. The Company was founded in 2021 by initial investors BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich<ref>{{Cite web|url=https://pharmaphorum.com/views-and-analysis/inside-moonlakes-raid-on-merck-kgaas-inflammatory-disease-hopeful-sonelokimab|title=Inside MoonLake's raid on Merck KGaA's inflammatory disease hopeful sonelokimab|website=pharmaphorum|date=14 May 2021 }}</ref><ref>{{Cite web |title=sec.gov, prelim. proxy statement |url=https://www.sec.gov/Archives/edgar/data/1821586/000121390021055441/prem14a_helixacq.htm}}</ref>, when Sonelokimab was in-licensed from Merck KGaA, of [[Darmstadt]], [[Germany]].<ref>{{Cite web |title=Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095) |url=https://www.merckgroup.com/en/news/statement-on-out-licensing-agreement-sonelokimab-03-05-2021.html}}</ref><ref>{{Cite web|url=https://www.fiercebiotech.com/biotech/moonlake-debuts-cosentyx-challenger-from-merck-kgaa|title=MoonLake debuts with Cosentyx challenger from Merck KGaA | Fierce Biotech}}</ref> |
MoonLake Immunotherapeutics (‘MoonLake’) ([[Nasdaq|NASDAQ]]: MLTX) is a clinical-stage biopharmaceutical company, headquartered in [[Zug]], [[Switzerland]], focused on developing medicines for inflammatory diseases. The Company was founded in 2021 by initial investors BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich<ref>{{Cite web|url=https://pharmaphorum.com/views-and-analysis/inside-moonlakes-raid-on-merck-kgaas-inflammatory-disease-hopeful-sonelokimab|title=Inside MoonLake's raid on Merck KGaA's inflammatory disease hopeful sonelokimab|website=pharmaphorum|date=14 May 2021 }}</ref><ref>{{Cite web |title=sec.gov, prelim. proxy statement |url=https://www.sec.gov/Archives/edgar/data/1821586/000121390021055441/prem14a_helixacq.htm}}</ref>, when Sonelokimab was in-licensed from Merck KGaA, of [[Darmstadt]], [[Germany]].<ref>{{Cite web |title=Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095) |url=https://www.merckgroup.com/en/news/statement-on-out-licensing-agreement-sonelokimab-03-05-2021.html}}</ref><ref>{{Cite web|url=https://www.fiercebiotech.com/biotech/moonlake-debuts-cosentyx-challenger-from-merck-kgaa|title=MoonLake debuts with Cosentyx challenger from Merck KGaA | Fierce Biotech}}</ref> |
||
Latest revision as of 09:18, 14 November 2024
 | Review waiting, please be patient.
This may take 6 weeks or more, since drafts are reviewed in no specific order. There are 1,263 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 27 July 2024 by CFA (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
| Submission declined on 27 March 2024 by Theroadislong (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by Theroadislong 7 months ago.
| |
| Submission declined on 26 March 2024 by DoubleGrazing (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by DoubleGrazing 7 months ago.
| |
Comment: References are mainly press releases and other run-of-the-mill articles that don't count towards notability per WP:ORGTRIV. C F A 💬 21:03, 27 July 2024 (UTC)
- Comment: The current references 3, 8 and 14 might give suitable coverage to count toward WP:NCORP but I think there needs to be a clearer story about the company. I would suggest removing the press releases and statements about shares that don't add to notability and don't seem to support any specific statements in the article. Mgp28 (talk) 14:51, 27 July 2024 (UTC)
MoonLake Immunotherapeutics (‘MoonLake’) (NASDAQ: MLTX) is a clinical-stage biopharmaceutical company, headquartered in Zug, Switzerland, focused on developing medicines for inflammatory diseases. The Company was founded in 2021 by initial investors BVF Partners LP, Merck KGaA, Florian Schönharting, Simon Sturge, Arnout Ploos van Amstel, Dr. Jorge Santos da Silva, and Dr. Kristian Reich[1][2], when Sonelokimab was in-licensed from Merck KGaA, of Darmstadt, Germany.[3][4]
Their primary therapeutic, Sonelokimab, is an investigational Nanobody designed to treat inflammatory diseases by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, Sonelokimab is designed to target inflammation sites directly and, due to its smaller size compared to typical monoclonal antibodies, potentially offers better tissue penetration.[5][6]
In May 2021, positive results of a Phase IIb trial of Sonelokimab for the treatment of patients with moderate to severe psoriasis were published in the peer-reviewed medical journal, The Lancet.[6][7]
MoonLake is progressing the clinical development of Sonelokimab for the treatment of inflammatory diseases, including hidradenitis suppurativa[8] and psoriatic arthritis.[9]
In April 2022, MoonLake combined with Helix Acquisition Corp., a special purpose acquisition vehicle, becoming a Nasdaq-listed company with the ticker symbol MLTX.[10]
References
[edit]- ^ "Inside MoonLake's raid on Merck KGaA's inflammatory disease hopeful sonelokimab". pharmaphorum. 14 May 2021.
- ^ "sec.gov, prelim. proxy statement".
- ^ "Merck Statement on the Out-licensing Agreement for Investigational sonelokimab (M1095)".
- ^ "MoonLake debuts with Cosentyx challenger from Merck KGaA | Fierce Biotech".
- ^ Iznardo, H. (12 August 2021). "Dual inhibition of IL-17A and IL-17F in psoriatic disease". Therapeutic Advances in Chronic Disease. 12. doi:10.1177/20406223211037846. PMC 8366125. PMID 34408825.
- ^ a b "Sonelokimab shows promise in Phase II psoriasis trial".
- ^ Papp, K.A. (2021). "IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study". The Lancet. 397 (10284): 1564–1575. doi:10.1016/S0140-6736(21)00440-2. PMID 33894834.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa". 13 November 2023.
- ^ "Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis". 15 November 2023.
- ^ "MoonLake over the moon with $230M SPAC deal for llama antibodies to challenge Novartis' Cosentyx | Fierce Biotech".
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.